<DOC>
	<DOCNO>NCT00067002</DOCNO>
	<brief_summary>The goal clinical research study learn combine cord blood unit make cell `` take '' fast recipient help improve result cord blood transplant .</brief_summary>
	<brief_title>Randomized Double Cord Blood Transplant Study</brief_title>
	<detailed_description>Cord blood source blood form cell use transplantation . The major problem type transplant small number blood form cell available cord unit , may delay `` take '' graft recipient . Two strategy may use try overcome problem . One method combination 2 unit cord blood grow cord blood cell laboratory transplant order increase number . Participants randomly assign ( toss coin ) one two group . If assign Study Arm 1 , receive two cord blood unit combine without grow cell laboratory . If assign Study Arm 2 , receive one cord blood unit combine one cord blood unit grown laboratory two week receive . Neither doctor know advance arm assign . Placement central venous catheter collection `` back-up '' stem cell : Before back-up stem cell collect receive chemotherapy , require placement hollow plastic tube ( catheter ) large vein inside body . This catheter use draw blood give medication fluid . The catheter insert skin upper chest extends right side heart . Your doctor explain procedure detail , require sign separate consent form . Collection back stem cell : Because collect additional cell donor cord blood possible transplant cord blood fails , back blood bone marrow sample collect frozen high dose chemotherapy begin . Peripheral blood progenitor cell collection ( Leukapheresis ) : Before collection blood stem cell , treat drug call granulocyte colony stimulate factor ( G-CSF ) , cause important stem cell marrow move peripheral blood collect . This medication give shot skin day 3 - 7 day , time blood stem cell collect central catheter 3-4 hour out-patient procedure . In case `` good vein '' access , silicone venous catheter may need collect blood . Bone Marrow Collection : If leukapheresis perform successfully , receive general anesthesia operating room multiple needle stick hip bone order collect bone marrow . Only small part bone marrow ( &lt; 5 % ) take . Selection another donor alternate source stem cell : If bone marrow back-up blood stem cell collect , family member whose bone marrow close match choose back donor . The potential donor would test performed assure he/she eligible donate . High-dose therapy : Your bone marrow transplant doctor give one four chemotherapy treatment , discuss . If acute lymphoblastic leukemia , lymphoma , Hodgkin 's disease , chronic lymphocytic leukemia , acute myelogenous leukemia , myelodysplastic syndrome , chronic eosinophilic leukemia chronic myelogenous leukemia , less 61 year old , receive high-dose chemotherapy , may assign Treatment Regimen # 1 - fludarabine-thiotepa-melphalan . Patients ALL may assign Treatment Regimen # 1 # 3 , depend doctor 's evaluation , age physical fitness . You receive melphalan single dose Day -8 , thiotepa single dose Day -7 , follow fludarabine give day 4 day row ( Days -6 -3 . Rituximab may give Day -9 appropriate disease . Day 0 day transplantation , negative day number use label treatment day transplant . If disease list , bone marrow transplant past , physical make less likely tolerate high-dose therapy well , less aggressive Treatment Regimen # 2 , Fludarabine , Cyclophosphamide low dose total body irradiation . The fludarabine give Days -6 , -5 , -4 , -3 . The cyclophosphamide give Day -6 . Irradiation give day -1 . Rituxan may give Day -7 appropriate disease . If acute lymphoblastic leukemia , 50 year old young , doctor decide full-dose Total body irradiation best treatment , assign Treatment Regimen # 3 - total body irradiation-VP16 . You receive total body irradiation Days -7 , -6 , -5 -4 , follow VP16 ( also know etoposide ) single dose Day -3 . Rituximab may give Day -8 appropriate disease . All chemotherapy , fluids medication must give vein infuse catheter . Once backup stem cell collect , patient admit hospital Day -9 begin receive fluid . Chemotherapy may stop intolerable side effect occur . Expansion expand cord blood : On Day -14 , Treatment Group 2 , one two cord blood unit thaw treated MD Anderson Stem Cell Laboratory vitamin-like growth factor 2 week give back day zero described . A small amount cord blood cell ( less 3 % ) use laboratory procedure measure quality product . The CliniMACS System medical device use separate type blood cell blood remove body leukapheresis . These separated cell process use treatment stem cell transplant . Transplantation cord blood : If Treatment Group 1 , two day follow completion high-dose therapy ( Day 0 ) , unit cord blood thaw infused ( one time ) catheter . Each unit take 30 minute infuse . Patients Treatment Group 2 receive one unit cord blood go expansion cell , follow infusion unit grown laboratory 14 day . Graft versus host disease ( GVHD ) preventive therapy : GVHD result reaction transplant cord blood cell certain tissue body . In attempt prevent decrease severity GVHD , receive two drug . Mycophenolate mophetyl ( MMF ) pills give start three day transplant , continue day 30 cord blood transplant . If take pill , drug give catheter . If develop GVHD , use MMF may prolong . Tacrolimus give 24 hour continuous infusion 3-6 week . Around Day 30 40 ( engraftment ) , tacrolimus change pill give daily 6-9 month . The number tacrolimus pill may vary accord blood level drug , usually 1 - 5 . This medicine use 6-9 month ( long chronic GVHD occur ) . You remain study long disease return . If disease return , take study may offer participation another study treat outside study . Follow-up transplant : After leave hospital , see regularly Department Blood Marrow Transplantation MD Anderson . The frequency visit may vary , may often daily . Blood ( 1-2 tablespoon ) urine test perform . The frequency blood test may also vary , may perform daily . Patients need bone marrow sample collect transplant 1 month , 3-4 month , 5-7 month transplant . After , bone marrow sample collect year , indefinitely . To collect bone marrow sample , area hip chest bone numb anaesthetic small amount bone marrow withdrawn large needle . Patients lymphomas Hodgkin 's disease need CT scan thorax , abdomen , pelvis perform transplant 1 month , 3-4 month , 5-7 month transplant . After do yearly . This investigational study . All treatment drug FDA approve commercially available . A total 110 patient may take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>1 . DiseaseSpecific Eligibility Requirements : Patients must one follow hematologic malignancy : 1 . Acute Myelogenous Leukemia ( AML ) , Myelodysplastic Syndrome ( MDS ) 2 . Acute Lymphoblastic Leukemia ( ALL ) 3 . Chronic Myelogenous Leukemia ( CML ) 4 . NonHodgkin 's Lymphoma ( NHL ) 5 . Hodgkin 's Disease ( HD ) 6 . Chronic Lymphocytic Leukemia ( CLL ) 7 . Chronic eosinophilic leukemia Philadelphia chromosome negative CML . 2 . Greater 1 month old &lt; =60 year old full myeloablative therapy . 3 . Patients must two CB unit available match patient 4 , 5 , 6/6 HLA class I ( serological ) II ( molecular ) antigen . Each cord must contain least 1E7 total nucleated cells/Kg recipient body weight prethawed fraction . 4 . Patient must willing undergo bone marrow harvest peripheral blood progenitor cell ( PBPC ) collection use case engraftment failure . If patient unable fails successfully undergo collection , family member must identify donate hematopoietic stem cell haploidentical transplant case engraftment failure . If autologous hematopoietic stem cell procure due marrow contamination malignancy , due harvest failure , haploidentical relative available willing donate , two cord blood unit use backup graft . 5 . Continuation Criteria # 4 : These unit identify prior enrollment study . 6 . Regimen 1 ( Myeloablative mel/thiotepa/fludarabine ) : 1.Patients ALL , HD , NHL , AML , MDS , CML , CLL Chronic eosinophilic leukemia candidate full myeloablative therapy . 2.Performance score least 60 % Karnofsky ( age &gt; = 12 year ) , Lansky PlayPerformance Scale ( age &lt; 12 year ) . 3.Age &gt; =1 month &lt; =60 year ( highdose ) . 7 . Continuation Criteria # 6 : 4.Adequate major organ system function demonstrate : . Left ventricular ejection function least 40 % . b.Pulmonary function test demonstrate diffusion capacity least 50 % . predict ( highdose ) . c.Creatinine &lt; 1.6 mg/dL . d.serum glutamate pyruvate transaminase ( SGPT ) /bilirubin &lt; = 2.0 x normal ( highdose ) . 8 . Eligibility Regimen 2 ( Nonmyeloablative CyFluTBI ) : 1 . Patients ALL , AML , MDS , CML , NHL , CLL , Chronic eosinophilic leukemia HD candidate full myeloablative therapy . All patient receive prior autologous transplant eligible . 2 . Performance score least 60 % Karnofsky PS &lt; 3 ( ECOG ) ( age &gt; = 12 year ) , Lansky PlayPerformance Scale ( age &lt; 12 year ) 3 . Age &gt; = 1 month &lt; =80 year 9 . Continuation Criteria # 8 : 4 . Left ventricular ejection function least 30 % ; 5 . Pulmonary function test demonstrate diffusion capacity least 40 % predict ; 6 . Creatinine &lt; 3.0 mg/dL ; 7 . SGPT &lt; = 4.0 x normal . 10 . Regimen 3 ( Myeloablative VP16TBI ) : 1 . Patients ALL candidate myeloablative therapy , require TBIcontaining regimen . 2 . Performance score least 60 % Karnofsky PS &lt; 2 ( ECOG ) ( age &gt; = 12 year ) , Lansky PlayPerformance Scale ( age &lt; 12 year ) . 3 . Age &gt; = 1 month &lt; =50 year . 4 . Organ function requirement : . Left ventricular ejection function least 50 % . b . Pulmonary function test demonstrate diffusion capacity least 50 % predict . c. Creatinine &lt; 1.6 mg/dL . d. SGPT &lt; = 2.0 x normal . 1 . HIV positive . 2 . Pregnancy . 3 . Serious medical Condition . 4 . Patients sign &amp; symptom lead positive lumbar puncture ( malignant cell CSF ) document metastatic parenchymal disease ineligible study . 5 . Availability appropriate , willing , HLAmatched relate donor .</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>ALL</keyword>
	<keyword>Leukemia , Lymphocytic , Acute</keyword>
	<keyword>AML</keyword>
	<keyword>Leukemia , Myelocytic , Acute</keyword>
	<keyword>CML</keyword>
	<keyword>Leukemia , Myeloid , Chronic</keyword>
	<keyword>NHL</keyword>
	<keyword>Lymphoma , Non-Hodgkin</keyword>
	<keyword>double cord blood transplant</keyword>
	<keyword>expand cord blood transplant</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Alkeran</keyword>
	<keyword>Thiotepa</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Fludarabine phosphate</keyword>
	<keyword>Fludara</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Neosar</keyword>
	<keyword>Mesna</keyword>
	<keyword>Mesnex</keyword>
</DOC>